Literature DB >> 8471414

High clearance of (S)-warfarin in a warfarin-resistant subject.

H O Hallak1, P J Wedlund, M W Modi, I H Patel, G L Lewis, B Woodruff, A A Trowbridge.   

Abstract

A 30 year old black male required a 60 mg daily dose of warfarin to elicit a therapeutic anticoagulant response (normal warfarin dose 2.5-10 mg day-1; maximum 15 mg day-1). Hereditary warfarin resistance was suspected after compliance, diet, concurrent medication and any gastrointestinal disorder were eliminated as contributory causes. The disposition of vitamin K and vitamin K epoxide was examined in the propositus, his two sisters and 13 control black male subjects. Each subject was given an i.v. bolus dose (5 mg) of vitamin K prior to and after 2 weeks of warfarin therapy (5 mg day-1). The oral clearances of (S)- and (R)-warfarin were also measured in each subject during the last day of warfarin therapy. The mean (+/- s.d.) systemic clearance of vitamin K was similar in all subjects before (114 +/- 35 ml min-1) and after (112 +/- 40 ml min-1) warfarin therapy. The mean (+/- s.d.) AUC value for vitamin K epoxide was increased by warfarin treatment (6.5 +/- 5.4 micrograms ml-1 min before and 139 +/- 78 micrograms ml-1 min after) in all subjects. In the propositus, the oral clearance of (S)-warfarin (14.5 ml min-1) and the clearance ratio for (S)/(R)warfarin (2.6) differed by more than 7 standard deviations from the control group (4.3 +/- 1.1 ml min-1 and 1.2 +/- 0.2, respectively). In one sister of the propositus, the stereoselective disposition of warfarin was comparable with that of her brother ((S)-warfarin clearance = 16.2 ml min-1; and (S)/(R)-warfarin clearance ratio = 2.7).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8471414      PMCID: PMC1381587          DOI: 10.1111/j.1365-2125.1993.tb05703.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Pharmacokinetic implications of stereoselective changes in plasma-protein binding: warfarin/sulfinpyrazone.

Authors:  S Toon; W F Trager
Journal:  J Pharm Sci       Date:  1984-11       Impact factor: 3.534

2.  Effect of enteral nutrition on warfarin therapy.

Authors:  M D Parr; K E Record; G L Griffith; J V Zeok; E P Todd
Journal:  Clin Pharm       Date:  1982 May-Jun

3.  Resistance to oral anticoagulant therapy - case report and review of literature.

Authors:  Y K Kueh; B K Ee; P C Teoh
Journal:  Singapore Med J       Date:  1982-04       Impact factor: 1.858

4.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

5.  Hereditary warfarin resistance. Investigation of a rare phenomenon.

Authors:  B M Alving; M P Strickler; R D Knight; C F Barr; J L Berenberg; C C Peck
Journal:  Arch Intern Med       Date:  1985-03

6.  Myocardial infarction after diet-induced warfarin resistance.

Authors:  F B Walker
Journal:  Arch Intern Med       Date:  1984-10

7.  Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine.

Authors:  C Banfield; M Rowland
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

8.  Familial warfarin resistance.

Authors:  R J Holt; C O Freytes
Journal:  Drug Intell Clin Pharm       Date:  1983-04

9.  Interaction of secobarbital with warfarin pseudoracemates.

Authors:  R A O'Reilly; W F Trager; C H Motley; W Howald
Journal:  Clin Pharmacol Ther       Date:  1980-08       Impact factor: 6.875

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  9 in total

1.  Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Authors:  N S Bazan; N A Sabry; A Rizk; S Mokhtar; O A Badary
Journal:  Ir J Med Sci       Date:  2013-06-27       Impact factor: 1.568

2.  In silico pharmacogenetics of warfarin metabolism.

Authors:  Yingying Guo; Paul Weller; Erin Farrell; Paul Cheung; Bill Fitch; Douglas Clark; Shao-yong Wu; Jianmei Wang; Guochun Liao; Zhaomei Zhang; John Allard; Janet Cheng; Anh Nguyen; Sharon Jiang; Steve Shafer; Jonathan Usuka; Mohammad Masjedizadeh; Gary Peltz
Journal:  Nat Biotechnol       Date:  2006-05       Impact factor: 54.908

3.  Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.

Authors:  Xu Steven Xu; Kenneth Moore; Paul Burton; Kim Stuyckens; Wolfgang Mueck; Stefaan Rossenu; Alexei Plotnikov; Michael Gibson; An Vermeulen
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 4.  Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.

Authors:  G Palareti; C Legnani
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

5.  Warfarin dose adjustments based on CYP2C9 genetic polymorphisms.

Authors:  Mark W Linder; Stephen Looney; Jesse E Adams; Nancy Johnson; Deborah Antonino-Green; Nichole Lacefield; Bonny L Bukaveckas; Roland Valdes
Journal:  J Thromb Thrombolysis       Date:  2002-12       Impact factor: 2.300

Review 6.  Pharmacogenetics: the therapeutic drug monitoring of the future?

Authors:  M H Ensom; T K Chang; P Patel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

Review 7.  Ethnic Diversity and Warfarin Pharmacogenomics.

Authors:  Innocent G Asiimwe; Munir Pirmohamed
Journal:  Front Pharmacol       Date:  2022-04-04       Impact factor: 5.988

Review 8.  Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.

Authors:  Jinhua Zhang; Zhijie Chen; Chunmei Chen
Journal:  Meta Gene       Date:  2016-07-05

9.  Phenotyping of CYP 4501A2 Activity by Total Overnight Salivary Caffeine Assessment (TOSCA) in Patients on Warfarin Treatment: A Cross-Sectional Study.

Authors:  Giovanni Tarantino; Domenico Capone; Paola Contaldi; Adriana Gianno; Mosca Teresa; Antonella Tufano
Journal:  Clin Appl Thromb Hemost       Date:  2017-10-09       Impact factor: 2.389

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.